What does this research mean for the field?

Dihydroxyacetone (DHA) may be beneficial for patients with vitiligo and erythropoietic protoporphyria (EPP) without demonstrated harm, but safety concerns regarding free-radical formation remain unresolved. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the clinical use and safety of dihydroxyacetone (DHA) in dermatological settings.

March 1, 2026Open Access

Clinical Use and Safety of Self-Tanner (Topical Dihydroxyacetone) in Dermatology: A Systematic Review

Key Points

To evaluate the clinical use and safety of dihydroxyacetone (DHA) in dermatological settings.
Conducted a systematic review of existing studies on DHA.
Analyzed studies involving patients with vitiligo and epidermolysis bullosa (EPP).
Considered safety assessments and concentration levels in various studies.
DHA showed potential benefits for treating vitiligo and EPP.
No studies reported harm from DHA use.
Most studies reviewed were of low quality, with few subjects, and some used excessive concentrations of DHA.

Abstract

DHA may have some use in patients with vitiligo and EPP. No studies demonstrated harm related to DHA use, though most studies were low-quality, conducted on a few humans or animals, occasionally with product concentrations over the threshold permitted by the European Commission. Unresolved safety concerns about free-radical formation require high-quality research to clarify DHA's long-term health impacts.

Read Full Paperexternally

AIに質問

Bookmark

View Full Paper